An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
ASCO 2024 – Enhertu nears its “ultralow” dream
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Bolt’s setback didn’t come out of the blue
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
Enhertu pushes on the HER2-low door once again
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
